**Core tip:** Gastric cancer (GC) remains a severe malignancy with high incidence and mortality rates. One major underlying mechanism of GC rapid progression, extensive spreading, and chemoresistance is tumor heterogeneity could be explained by the gastric tumor-initiating cell (GATIC). Since the initial identification of putative GATICs in 2007, substantial studies have been performed to investigate various aspects of GATICs. Here, we systemically discuss the tumor heterogeneity of GC from the view of GATICs by reviewing studies on the identification and validation of GATICs, origination of GATICs, plasticity of GATICs and its underlying mechanism, and current status of chemotherapeutic agents targeting GATICs.

INTRODUCTION
============

Gastric cancer (GC), with gastric adenocarcinoma as the most common histological type, is the fifth most common malignancy and the third leading cause of cancer-related death worldwide\[[@B1]\]. Despite its declining incidence and mortality rate in several developed countries, GC remains a common and deadly disease with a poor prognosis globally, especially in northeastern Asia and South America\[[@B2]\]. Although significant progress has been made regarding the development of anti-cancer therapeutic agents, chemoresistance and recurrence of GC are major obstacles for improving the overall survival rate of advanced GC patients\[[@B3]\]. Combined chemotherapy, such as fluoropyrimidine plus platinum derivatives, serves as the first-line treatment for patients with locally advanced or metastatic GC. Unfortunately, response rate of these patients to these major regimens is only approximately 50%, with overall survival ranging from 7 to 11 mo. For patients with relapsed GC, second-line treatment confers limited benefits of less than 6 mo\[[@B4],[@B5]\]. With the advance of new techniques, especially high-throughput sequencing of GC patients' primary tumor materials, even at the single cell level, investigators have revealed the essential roles of tumor heterogeneity underlying the mechanism of tumor recurrence and drug resistance\[[@B6]\].

Tumor heterogeneity is universally recognized as one of most fundamental features of malignancies. It is noteworthy that the inherent variations exist not only between patients with same type of malignancies (intertumor heterogeneity) but also within any individual tumor (intratumor heterogeneity)\[[@B7]\]. Intratumor heterogeneity implies the inherent temporal-spatial differences between distinctive subpopulations of tumor cells within the same tumor at both genetic and epigenetic levels\[[@B8]\]. In-depth sequencing technology enables the identification of different regions of a single tumor entity that harbor subclones with distinct genetic and epigenetic features\[[@B9]\]. Moreover, non-cancerous cells (for instance, stromal cells, infiltrating immune cells, extracellular matrix, vascular endothelia cells, *etc*.) interact with the surrounding cancerous subpopulations and form the regional microenvironments\[[@B10]\]. Consequently, tumoral and microenvironmental factors confer distinctive subpopulations of cancer cells with distinctive biological features and differential responses to chemotherapeutics. This adds to the complexity of cancer treatment and leads to lethal consequences, including tumor relapse and chemoresistance. Regarding gastric cancer, multiple studies have demonstrated its intratumor heterogeneity at molecular, histological, and phenotypic levels\[[@B7]\]. For instance, novel molecular-based classification launched by the Cancer Genome Atlas in 2014 and other genomic studies not only highlight the heterogeneity of GC but also imply its negative influence on tumor response to therapeutics agents targeting human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), c-MYC, *etc*\[[@B11]-[@B13]\].

Two major models have been proposed to interpret intratumor heterogeneity. The clonal evolution (CE) model posits that somatic mutations stochastically occur on various clones within the tumor, leading to their differential growth patterns. Mutated clones with growth advantages will expand, whereas others with disadvantageous mutations will be outcompeted. As this scenario might be presented at different sites and different stages during cancer progression, the spatial-temporal tumor heterogeneity is consequently installed\[[@B14]\]. Alternatively, the cancer stem cell (CSC)/tumor-initiating cell (TIC) model was introduced based on the discovery that only a minor subpopulation of cancer cells generates tumor *in vivo* and maintains its self-renewal potential\[[@B15]\]. Both CSCs and TICs are widely used in the literature. However, the term of TIC highlights the capacity of these cells to (re)generate tumors during *in vivo* serial xenotransplantation, which is currently the gold standard for functionally validating and evaluating their tumorigenic capacity and self-renewal potential\[[@B16]\]. Indeed, key features of these distinctive subsets of cancer cells include: (1) Initiating and maintaining tumor growth; (2) preserving self-renewal potential; (3) giving rise to both tumorigenic and non-tumorigenic cancer cells; and (4) being highly resistant to chemotherapy\[[@B17]\]. Consequently, TICs establish intratumor heterogeneity by generating a cellular hierarchy, with very primitive TICs at the apex generating both daughter TICs and more differentiated non-TICs downwards. Recent genetic and functional studies not only identify somatic mutations within certain TIC clones but also demonstrate that these mutations influence their phenotypic features, generating distinctive TIC subclones\[[@B18]\]. As CE and TIC models are not mutually exclusive, these two models could be integrated. Remarkably, well-differentiated cells are shown to regain TIC properties through the process of dedifferentiation\[[@B19]\]. Collectively, these studies indicate that TICs are in dynamic status with substantial plasticity that is subjected to the regulation of multiple intrinsic and extrinsic factors\[[@B20],[@B21]\]. These findings contribute to a comprehensive interpretation of intratumor heterogeneity through evolving characterization of TICs.

GC is both genetically and phenotypically heterogeneous, which could be explained by gastric tumor-initiating cells (GATICs) that interact with genetic/epigenetic and microenvironmental factors\[[@B22],[@B23]\]. Here we systemically review the GATICs from multiple perspectives including: (1) Identification and origination of GATICs; (2) plasticity of GATICs and their regulatory mechanisms; and (3) clinical implications of GATIC-targeted therapy.

Identification and validation of GATICs
---------------------------------------

Identification of GATICs is executed from three major aspects: Putative cell surface markers, efflux potential, and chemotherapeutics of GATICs\[[@B24]\]. Further functional validation of GATICs can be achieved with serial xenotransplantation of purified TIC subpopulation, which aims to evaluate its tumorigenicity and self-renewal capacity *in vivo*\[[@B25]\].

Identification of GATICs by cell surface markers
------------------------------------------------

GATICs account for a minor subpopulation of GC cells that are endowed with significantly enhanced tumorigenic and self-renewal capacities. Key features of GATICs are partially similar with the characteristics of normal gastric stem cells (GSCs). Therefore, one major strategy of GATIC identification is through the detection of specific cell surface markers expressed on GSCs\[[@B26]\].

CD44 was the first putative cell surface marker identified for GATICs. As a universally recognized stem cell marker, this transmembrane glycoprotein mainly mediates cell-cell interaction, cell adhesion, and migration in healthy tissues\[[@B27]\]. Studies have shown that CD44(+) tumor cells regenerate heterogeneous tumors, demonstrate self-renewal capacity *in vivo*, and promote tumor progression, especially metastasis through oncogenic and stemness-related signaling pathways\[[@B28]\]. In 2009, Takaishi et al\[[@B29]\] demonstrated that fluorescence activated cell sorting (FACS)-sorted CD44(+) cells from three common GC cell lines exhibited enhanced TIC properties, including sphere formation *in vitro* and tumorigenicity in immune-deficient mice during serial transplantation, whereas CD44 knockdown induced compromised TIC properties both *in vitro* and *in vivo*. More specifically, CD44v8-10, a predominant CD44 variant, was identified as a specific GATIC marker, as exogenous overexpression of CD44v8-10, rather than standard CD44, improved the tumorigenicity *in vivo*\[[@B30]\]. Since combination of multiple cell surface markers improved the specificity of TIC identification, several studies have further demonstrated other putative GATIC subpopulations expressing both CD44 and other cell surface markers, including EpCam, CD24, *etc*\[[@B31],[@B32]\]. Notably, CD44(+)CD54(+) circulating tumor cells captured from GC patients' peripheral blood enabled sphere formation even at the single cell level. Moreover, the rapidly developed CD44(+)CD54(+) cell-derived tumors histologically resembled the matching primary tumor, indicating the improved specificity of GATIC population co-expressing multiple putative cell surface markers\[[@B33]\].

CD90 was recently identified as a GATIC specific cell surface marker. Indeed, it is recognized as a marker for a variety of normal and cancer stem cells\[[@B34]\]. Jiang et al\[[@B35]\] identified a GATIC population in primary gastric tumors characterized by its CD90 phenotypic features. CD90(+) cells were enriched in TIC-enriched cell culture condition, and these cells enabled tumor initiation with the minimum of 1 × 10^3^ cells. Remarkably, the cellular hierarchy of GC could be restored by CD90(+) cells at a single cell level, strongly indicating their self-renewal capacity in GC. It was further shown that both tumorigenicity and tumor progression could be compromised by anti-ERBB2 therapeutic monoclonal antibody through inhibiting CD90(+) cell population in GC tumor mass\[[@B36]\].

Leucine rich repeat containing G-protein coupled receptor 5 (Lgr5) is a well-investigated stem cell marker across the gastrointestinal tract. Lgr5(+) stem cells were shown to drive self-renewal in the stomach and establish long-lived gastric units\[[@B37]\]. Thus, the role of Lgr5(+) cells during the initiation and progression of gastric malignancies has also been studied. Simon et al\[[@B38]\] reported that an elevated number of Lgr5(+) stem cells might be involved in gastric tumorigenesis. Moreover, Gong et al\[[@B39]\] showed that therapeutic antibodies targeting Lgr5(+) cells significantly inhibited tumor growth and prevented tumor recurrence, and Wang et al\[[@B40]\] demonstrated that GATIC-enriched tumor spheres highly expressed Lgr5(+).

Aldehyde dehydrogenase (ALDH) is another universal marker for multiple cancers, including GC\[[@B41]\]. It is a family of enzymes that catalyze the oxidation of aromatic aldehydes to carboxyl acids. Multiple studies have shown that ALDH(+) GC cells not only contribute to the generation of heterogeneous tumor entity and the maintenance of GATIC features but also facilitate chemoresistance and tumor relapse\[[@B42],[@B43]\]. An extensive study that profiled the expression of putative GATIC cell markers even claims that ALDH is one of the most specific biomarkers for GATICs in highly tumorigenic and chemoresistant non-cardia GC, regardless of histological type\[[@B44]\].

Furthermore, it has been accepted that combination of multiple TIC markers could potentially/possibly increase the specificity of identified TIC subpopulations. In GC, the most common pattern of combined GATIC marker expression is CD44 plus another identified marker. All the putative GATIC markers, including GATICs expressing single and multiple cell surface markers, are summarized in Table [1](#T1){ref-type="table"}.

###### 

Putative cell surface markers of gastric tumor-initiating cell

  **Putative marker**   **Tumor sphere formation (*in vitro*)**   **Tumor formation during serial engraftment (*in vivo*)**   **Limiting dilution assay**   **Chemo-resistance**   **Others**                                                                                                                                 **Ref**.
  --------------------- ----------------------------------------- ----------------------------------------------------------- ----------------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------
  CD44                  \+                                        \+                                                          Not conducted                 \+                     \(1\) Capacity of cell differentiation (2) Giving rise to both CD44+ and CD44- GC cells (3) Independent prognostic factor of GC patients   Takaishi et al\[[@B29]\] Yoon et al\[[@B119]\]
  CD44/CD24             \+                                        \+                                                          \+                            Not conducted          Capacity of cell differentiation                                                                                                           Zhang et al\[[@B32]\]
  CD44/CD54             \+                                        \+                                                          \+                            Not conducted          \(1\) Capacity of cell differentiation (2) Detectable from peripheral blood                                                                Chen et al\[[@B33]\]
  CD44/CD26             \+                                        \+                                                          Not conducted                 \+                     /                                                                                                                                          Nishikawa et al\[[@B127]\]
  CD44/EpCam            \+                                        \+                                                          \+                            \+                     \(1\) Capacity of cell differentiation (2) Restoration of histological heterogeneity from single CD44/EpCam+ cell                          Han et al\[[@B31]\]
  CD44v810/EpCAM        \+                                        \+                                                          \+                            \+                     CD44v8-10 but not CD44 standard increase the frequency of tumor initiation                                                                 Lau et al\[[@B30]\]
  CD90                  \+                                        \+                                                          \+                            \+                     Restoration of cellular hierarchy from single CD90+ cell                                                                                   Jiang et al\[[@B35]\]
  CD133                 \+                                        \+                                                          Not conducted                 \+                     Independent prognostic factor of GC patients                                                                                               Zhang et al\[[@B128]\]
  Lgr5                  \+                                        \+                                                          Not conducted                 Not conducted          /                                                                                                                                          Wang et al\[[@B40]\]
  ALDH                  \+                                        \+                                                          \+                            \+                     /                                                                                                                                          Nishikawa et al\[[@B42]\]
  ALDH1/REG4                                                                                                                                                                                                                                                                                                                  Katsuno et al\[[@B45]\]
  Oct4/Sox2/Nanog       \+                                        \+                                                          Not conducted                 \+                     Independent prognostic factor of GC patients                                                                                               Liu et al\[[@B129]\]

ALDH: Aldehyde dehydrogenase; GC: Gastric cancer.

Notably, several studies have demonstrated a significant correlation between reported GATIC markers and histological subtypes of GC. For instance, CD44 is more frequently and highly expressed in the intestinal subtype GC cells with moderate differentiation, whereas ALDH correlated with the diffuse subtype and epithelial-mesenchymal transition (EMT) phenotype\[[@B45],[@B46]\]. Moreover, Lei et al\[[@B47]\] recently conducted novel classification of GC based on the analysis of gene expression patterns and claimed that the mesenchymal subtype had TIC properties such as high expression of putative GATIC markers, maintenance of an undifferentiated state, and enhanced activity of TIC-associated signaling pathways\[[@B48]\]. These studies further highlight tumor heterogeneity in terms of GATICs with specific markers differentially expressed by gastric malignancies.

Identification of GATICs by differential efflux potential
---------------------------------------------------------

Although identification of TICs through putative cell surface markers has been extensively established, the specificity and accuracy of these markers are still under debate as the inconsistency of studies investigating the same markers has been observed\[[@B49]\]. An alternative to identify TICs is the differential efflux potential-based strategy. In principle, TICs highly express ATP-binding cassette (ABC) transporters, which facilitate the cells' ability to export foreign bodies, such as therapeutic compounds, and thereby endow TICs with key features of reduced chemosensitivity and enhanced multidrug resistance. Consequently, after exposing a whole cancer cell population to Hoechst 33342, a classic cell dye, a differential amount of residual Hoechst 33342 within non-TICs and TICs could be observed. Most cancer cells with much retained Hoechst 33342 were from the main population (MP), whereas the minor subpopulation of TICs with significantly eliminated Hoechst 33342 were defined as the side population (SP). As FACS enables the discrimination between MP and SP, this strategy has been widely applied to identify the TIC population\[[@B50]\]. In GC, Fukuda et al\[[@B51]\] and She et al\[[@B52]\] respectively demonstrated that SP cells isolated from either GC cell lines or tumor samples exhibited improved sphere formation *in vitro* and tumorigenicity *in vivo*. Moreover, Tian et al\[[@B53]\] isolated SP cells from multiple GC cells lines and showed that SP cells not only conferred an asymmetric cell division pattern but also exhibited elevated resistance to cisplatin and adriamycin, both of which are key characteristics of GATICs. Although these studies imply that SP cells possibly possess an enriched population of GATICs, a recent study suggested that not all SP cells contain GATICs. In this study, SP cells from BCG823 cell line showed equal tumorigenicity as MP cells, indicating that SP alone may not be potent enough to distinguish GATICs from normal GC cells\[[@B54]\].

Purification of GATICs through chemotherapeutic reagents
--------------------------------------------------------

Apart from the above-mentioned strategies, chemotherapeutics screening can also be applied to obtain TIC populations that are inherently resistant to drugs. In fact, Xue et al\[[@B55]\] reported a vincristine-preconditioning approach for GC cell line SGC7901 to obtain cells with increased GATIC markers, not only forming 3D structures resembling the differentiated gastric crypts but also displaying mesenchymal characteristics. A similar study conducted by Xu et al\[[@B56]\] showed that preconditioning treatment of 5-fluorouracil to SCG7901 and AGS cell lines enriched the population with up-regulated GATIC markers, enhanced tumorigenicity and self-renewal *in vivo*, and enhanced toleration to the insults from chemotherapy.

ORIGIN OF GATICS
================

As GC itself is highly heterogeneous, its initiation is also a multi-stepwise process critically involving multiple factors. Genetic factors, infection of *H. pylori*, environmental elements, *etc*. contribute to the abnormal alteration of the gastric epithelium, especially metaplasia and dysplasia, which pave the basis for final development of gastric malignancies\[[@B57],[@B58]\]. During this process, certain types of cells are abnormally transformed into GATICs, which install the cellular hierarchy with itself at the apex, giving rise to both self-renewal, tumorigenic GATICs and differentiated non-TICs. The major potential origins of GATICs are normal gastric stem cells and bone marrow-derived cells (Figure [1](#F1){ref-type="fig"}). Recent studies also preliminarily suggest that dedifferentiated gastric epithelial cells (GECs) could regain stemness features under certain circumstances, indicating its potential role as an origin of GATICs\[[@B59],[@B60]\]. However, more rigorous and sufficient data are needed to support this proposal.

![Origination of gastric tumor-initiating cells. A: Evidence suggests that the gastric stem cell (GSC) is one major origin of the gastric tumor-initiating cell (GATIC). GSCs exist in the isthmus and bottom of the gastric pit. Certain genetic, epigenetic, and/or environmental factors potentially transform these GSCs into malignant GATICs. For instance, Mist(+) and Villin(+) GSCs in the isthmus and Lgr5(+) GSCs in the bottom could act as the origins of GATICs through multiple signaling pathways; B: GATICs are also presumed to originate partially from bone marrow-derived cells (BMDCs). The recruitment of BMDCs to stomach by chemokines and other factors is in parallel with the multi-step progression of gastric cancer (GC), which lays the basis for the presumption that BMDCs undergo the malignant transformation into GATICs and promote GC development, the underlying mechanism of which requires further investigation.](WJG-24-2567-g001){#F1}

GATICs derived from normal gastric stem cells
---------------------------------------------

Gastric epithelial mucosa consists of four types of cells: chief cells, parietal cells, mucous cells, and enteroendocrine cells, all of which are derived from epithelial stem cells. These stem cells generate a cellular hierarchy of differentiation and proliferation and maintain the integrity of gastric mucosa\[[@B61]\]. Extensive studies of stem cells in the gastric epithelium identified a variety of GSCs with specific markers and restricted locations. For instance, Lgr5(+) cells at the bottom of adult pyloric glands\[[@B37]\], Sox2(+) cells located slightly above the bottom of pyloric and fundic glands, Villinβ-gal/(+) and Mist1(+) cells in the isthmus *etc*. are all GSCs with distinctive functions during normal development of the gastric mucosa\[[@B62],[@B63]\].

It has long been postulated that resident tissue stem cells are the major resource of TICs, as malignancies could arise from the stem or progenitor cells *in situ*\[[@B26]\]. In 2008, McDonald et al\[[@B64]\] firstly proposed that the expansion and spread of mutated GSCs underlie the local progression of GC. Since then, multiple oncogenic mutations in GSCs have been identified. Adenoma is initiated when mutational loss of adenomatous polyposis coli gene induced by tamoxifen occurred in Lgr5(+) stem cells\[[@B37]\]. Under circumstance of chronic inflammation, aberrant activation of Notch and mutational alteration of E-cadherin in Mist(+) stem cells in the isthmus induced the development of intestinal and diffuse type of GC, respectively\[[@B63]\]. Moreover, mice with disrupted Krüppel-like factor 4 (Klf4) in Villin(+) antral mucosa cells develop GC more frequently than mice with normal Klf4 function, indicating dysfunctional mutation of a tumor suppressor gene in GSCs can also induce gastric carcinogenesis\[[@B65]\]. Taken together, it is speculated that genetic alterations and mutations transform normal GSCs into oncogenic GATICs, which then initiate and promote tumor development. In other words, normal GSCs are a major putative origin of GATICs (Figure [1A](#F1){ref-type="fig"}).

GATICs derived from bone marrow-derived cells
---------------------------------------------

Bone marrow-derived cells (BMDCs) are recognized as the most primitive uncommitted stem cells in adult since they potentially possess substantial plasticity as well as exhibit motility, migrating towards the sites of inflammation or injury\[[@B66]\]. The potential role of BMDCs as a source of malignant cells was not been identified until 2004 when Houghton et al\[[@B67]\] discovered that GC could originate from bone marrow-derived sources. In that study, *Helicobacter* C57BL/6 mouse model showed that *H felis*-caused chronic inflammation and induced initiation and development of GC. This process was strikingly paralleled with the recruitment of BMDCs followed by dramatic population of bone marrow-derived glands in the abnormal gastric epithelial\[[@B67]\]. Varon et al\[[@B68]\] further confirmed that the multi-step abnormal development of gastric epithelial induced by *H. pylori* was accompanied by significant accumulation of BMDCs. Notably, approximately 25% of the dysplasia lesions were bone-marrow derived. These discoveries strongly indicated that BMDCs, as a potential source of GATICs, could undergo abnormal transformation and contribute to GC progression, especially by migrating into the stem cell microenvironment of inflammatory tissues (Figure [1B](#F1){ref-type="fig"})\[[@B69]\]. However, a recent study contradicted the claim and reported that BMDCs were only sporadically found in stroma and not the epithelium or glands of GC induced by carcinogens, including N-nitroso-N-methylurea and *H. felis*\[[@B70]\]. Therefore, more investigations are required to characterize further the process of aberrant transformation of BMDCs and to confirm them as a potential source of GATICs.

PLASTICITY OF GATICS AND ITS REGULATORY MECHANISMS
==================================================

Plasticity of GATICs
--------------------

As briefly mentioned above, both the CE model and TIC model are major proposals for the interpretation of intratumor heterogeneity. The CE model highlights the stochastic genetic/epigenetic alterations that occur in cancer cells at various sites and phases during cancer progression, resulting in the formation and expansion/extinction of different subpopulations of cancer cells with their own phenotypes\[[@B71]\]. In contrast, the TIC model stresses the essential role of highly tumorigenic and self-renewal TICs to generate daughter TICs with similar characteristics (symmetric division) and non-TICs with limited potential of self-renewal, tumorigenicity, and metastasis (asymmetric division)\[[@B72]\]. The co-existence of TICs and non-TICs with distinctive biological properties reflects the intratumor heterogeneity. Furthermore, it was repeatedly discovered that differentiated cancer cells could regain "stemness" under the regulation of multiple factors, demonstrating the existence of bidirectional conversion between TICs and non-TICs\[[@B73]\]. In light of this dynamic transition, TICs are more recognized as a phenotypic status or mode rather than a fixed subset of cancer cells, indicating that the plasticity of TICs plays an essential role in the intratumor heterogeneity\[[@B74]\]. Therefore, a unified model of CE and TICs was recently proposed to stress the plasticity of TICs: Primitive TICs with substantial capacity of tumorigenicity and self-renewal develop the cellular hierarchy. Meanwhile, they generate multiple subclones that subsequently acquire distinctive genetic mutations and/or epigenetics. Some subclones retain TIC features and continue to expand, whereas other subclones are in the non-TIC status. Nevertheless, a proportion of non-TIC subclones could reversely acquire TIC features under the regulation of genetic/epigenetic factors and/or tumor microenvironment (TME)\[[@B18]\].

In GC, GATIC plasticity could also be identified. Bessède et al\[[@B75]\] demonstrated that deletion of IQGAP1, a scaffold protein modulating cell plasticity and actin cytoskeleton, in the MKN74 GC cell line induced enhanced tumor sphere formation and increased expression of GATIC markers, both of which are major GATIC features *in vitro*. *In vivo* experiments further showed that *H. pylori*-induced gastric dysplasia was further enhanced by IQGAP1 deletion. Similarly, Yong et al\[[@B76]\] reported that CagA-positive *H. pylori* induced the transformation of MKN45 and AGS GC cell lines into TIC-like cells as they manifested corresponding properties *in vitro*. A mechanism investigation showed that CagA upregulated Nanog and Oct4 *via* the Wnt/β-catenin pathway, which underlies the process of TIC status transition. Moreover, multiple studies have shown that the dedifferentiation of mature gastric epithelial cells can reacquire stemness features, including tumor-initiation, expression of TIC markers, *etc*\[[@B60],[@B77],[@B78]\]. All these studies highlight TIC plasticity and demonstrate a dynamic conversion of cells with and without TIC properties when a variety of factors are involved in the process of regulation (Figure [2A](#F2){ref-type="fig"}).

![Plasticity of gastric tumor-initiating cells. A: Gastric tumor-initiating cells (GATICs) give rise to both daughter GATICs and non-TIC gastric cancer (GC) cells (asymmetric division) while maintain their self-renewal capacity and "stemness". Notably, recent studies demonstrate that differentiated non-TIC GC cells could undergo dedifferentiation and re-acquire the properties (or status) of GATICs. Thus, the bi-directional transition between TIC and non-TIC indicates the plasticity of GATICs, which is regulated by both genetic/epigenetic alterations and tumor microenvironmental factors; B: GATICs reside in the tumor-microenvironment, which consists of cancer cells (GATICs and non-TIC GC cells) as well as non-cancerous cells, such as cancer-associated fibroblast, extracellular matrix, blood supply, hypoxia (hypoxia-inducing factor), and other secreted factors, such as cytokines, growth factors. GATICs interact with these factors within the TIC niche, which exerts regulatory influence on the plasticity of GATICs through various signaling pathways.](WJG-24-2567-g002){#F2}

Regulatory mechanisms of GATICs and their plasticity
----------------------------------------------------

Both intrinsic factors (genetic and epigenetic alterations) and extrinsic factors (mainly tumor microenvironment) have been implicated in the regulation of GATICs and their plasticity (Figure [2](#F2){ref-type="fig"}).

**Genetic and epigenetic alterations:** Aberrantly dysregulated key effectors in several signaling pathways modulate gastric tumorigenesis and essential GATIC properties. Studies have shown that the activated hedgehog (HH) pathway significantly contributed to GC cell proliferation\[[@B79]\]. It was further demonstrated that sonic hedgehog (SHH) pathways are essential for maintaining the status of GATICs: Ptch and Gli1. Two SHH pathway key effectors were significantly overexpressed in GATIC-enriched sphere cultures. Significantly blocking this pathway not only decreased the expression of putative GATIC markers, including CD44 and CD24, but also reduced the self-renewal and tumorigenic capacity of GATICs, which are enriched in sphere cultures\[[@B80]\]. Nanog, a key transcription factor, not only maintained the self-renewal and pluripotency in embryonic stem cells but also contributed to the progression of multiple malignancies\[[@B81]\]. In GC, Nanog is aberrantly overexpressed in cancerous tissues. More importantly, it maintains the TIC features primarily through its interaction with multiple factors, especially the HH pathway and signal transducer and activator of transcription 3 (STAT3), which is another well-investigated regulating factor of GATICs\[[@B82]\]. Activated STAT3 has been observed in many types of cancers and is critically involved in cancer progression\[[@B83]\]. Jiang et al\[[@B84]\] recently reported that interleukin (IL)-17 promoted the invasive transformation of quiescent GATICs through facilitating phosphorylation and subsequent activation of STAT3. Exposure of quiescent GATICs to an optimal duration and concentration of IL-17 led to an increase in N-cadherin and vimentin, which are epithelial-to-mesenchymal transition (EMT)-related makers, as well as in the invasive and clonal proliferative abilities of GATICs\[[@B84]\]. Notably, epithelial cells that undergo the process of EMT acquire TIC phenotypes. Another EMT-contributing signaling pathway is the Wnt/β-catenin pathway, which reportedly maintains the self-renewal, tumorigenesis, and chemoresistance of TICs\[[@B85]\]. Oshima et al\[[@B86]\] reported that the Wnt/β-catenin pathway maintained the undifferentiated status of gastric progenitor cells, and co-activation of both Wnt and prostaglandin E2 induced sequential metaplasia, dysplasia, and malignant transformation of the gastric epithelium. Other studies have shown that the Wnt/β-catenin pathway induced the acquirement and maintenance of TIC features in GC\[[@B87]\]. Investigations of other major stemness-associated factors, including TGFβ, Notch1 *etc*., and their related signaling pathways hint their potential involvement in the maintenance of defined characteristics of TICs in certain types of cancers. However, more studies are required to validate their relationships with GATICs\[[@B88]-[@B90]\].

Similarly, epigenetic alterations also critically regulate TICs and their plasticity. The malignant transformation of somatic cells, maintenance of TIC self-renewal capacity, and bidirectional transition between TICs and non-TICs are all under the regulatory influence of epigenetic factors\[[@B91]\]. Major epigenetic variations, including DNA hypermethylation, histone modification, and silencing of both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have been shown to regulate GATICs. Activated oncogene ERas not only drives the tumorigenic growth but is also involved in maintaining the TIC properties in GC\[[@B92],[@B93]\]. Yashiro et al\[[@B93]\] discovered that ERas promoter methylation was found in six of seven GC cell lines without ERas expression, which could be reversed by DNA methyltransferase inhibitor. Loss of methylation in the promoter of ERas induced ERas activation and further increased SP cells in which GATICs were enriched. Tomita et al\[[@B94]\] reported that methylation and histone modification at the Tff1 promoter led to the extensive inactivation of the tumor suppressor gene Tff1 and further facilitated the initiation of GC in MNU-treated wild-type mice. The epigenetic silencing in the TFF1 promoter could be partially reversed by gastrin, indicating the role of epigenetic silencing in the plasticity of GC development. Moreover, epigenetic alterations could indirectly regulate the status of GATICs through influencing key regulators in TIC-related signaling pathways. Yoda et al\[[@B95]\] reported that aberrant methylation of DKK3, NKD1, and SFRP1, negative regulators of the WNT pathway, induced the activation of the Wnt/β-catenin pathway and further contributed to regulation of multiple aspects of GATIC functional activities. Wang et al\[[@B96]\] reported that hypomethylation of the SHH promoter increased the aberrant expression of SHH ligands in GC cells, leading to further enhanced SHH pathway activity and dysregulated GATIC properties. Non-coding RNA can also exert regulatory effects on GATICs in a similar manner. For instance, microRNA-106b down-regulated Smad7 and subsequently activated the TGF-β/Smad pathway, which in turn promoted the self-renewal and EMT characteristics of CD44(+) GC cells\[[@B97]\]. MicroRNA4835p was found to be overexpressed in GC spheroid cultures. Furthermore, this microRNA increased the expression of βcatenin and its downstream molecules, including cyclin D1, Bcl-2, and MMP2, which enhanced both invasiveness and self-renewal capacity of GC cells\[[@B98]\].

**Tumor microenvironments (TIC niches):** Apart from intrinsic regulation of GATICs and their plasticity by genetic and epigenetic alterations, TIC niches are also key GATIC regulators within the tumor microenvironment (TME) (Figure [2B](#F2){ref-type="fig"})\[[@B99]\]. In principal, TME is composed of fibroblastic stromal cells, endothelial and perivascular cells, immune cells, extracellular matrix (ECM), and networks of cytokines and growth factors, all of which play extensive roles in regulating GATICs\[[@B100]\]. It was reported that cancer-associated fibroblasts (CAFs) significantly increased the proportion of a side population (SP) of GC cells, with characteristics of cell stemness and the expression levels of GATICs markers in scirrhous gastric cancer cell lines. Mechanism investigation showed that this process was significantly influenced by the activity of TGF-β\[[@B88]\]. Bone marrow-derived myofibroblasts (BMFs) are also major components of GATIC niches. The expansion and relocation of BMFs create a mesenchymal stem cell niche to facilitate tumor progression\[[@B101]\]. BMF-conditioned medium induced the formation of GC spheres expressing stem cell signatures and exhibiting features of self-renewal, and EMT transition through TGF-β and Cxcr4/Cxcl12-dependent pathways\[[@B102]\]. Another fundamental characteristic of TIC niches is hypoxia. As tumor microenvironment is usually hypoxic, TICs are constantly under the pressure from hypoxia through the mediation of hypoxia-induced transcription factor 1α and 2α (HIF-1/2α)\[[@B103]\]. In GC, it was shown that HIF-1α induced EMT in GATIC-enriched spheroid cultures through the Snail signaling pathway\[[@B104]\]. Another study demonstrated that HIF-1α down-regulated the expression of CD133, a putative GATIC marker, in GC cell lines, suggesting that mTOR signaling is involved in the process\[[@B105]\]. Other major components in TIC niches, including tumor-associated macrophages, blood vessels, and soluble cytokines and growth factors, have been proven to regulate TIC activities and plasticity in multiples types of cancers. Therefore, it is reasonable to speculate that GITC niche components exert extensive regulatory influences on GATICs and its plasticity.

CLINICAL IMPLICATIONS OF TARGETING GATICS
=========================================

Chemotherapy plays an essential role in the comprehensive treatment of GC. Unfortunately, development of tumor resistance to conventional chemotherapeutic agents poses a major obstacle in the eradication of GC. Intratumor heterogeneity of GC essentially underlies the chemoresistance. The bulk of proliferating progenitor cells or differentiated tumor cells could be effectively targeted by anti-cancer drugs, whereas a minor proportion of GATICs remain unaffected by cytotoxic agents\[[@B106]\]. GATICs survive from chemotherapy and re-generate heterogeneous subpopulations of GC cells, giving rise to tumor recurrence and leading to poor prognosis of GC patients.

Mechanisms of GATIC chemoresistance
-----------------------------------

GATICs evade and/or tolerate the insults from chemotherapy through multiple routes. Firstly, GATICs highly express ABC transporters that function as efflux pumps of incoming reagents\[[@B107]\]. Consequently, GATICs constantly pump out anticancer drugs and avoid their cytotoxic effects\[[@B108]\]. Secondly, ALDH(+) GC cells are recognized as GATICs due to their substantially enhanced tumorigenicity and self-renewal capacity\[[@B109]\]. It was found that the expression of Notch1 and Shh was increased in this highly chemoresistant subpopulation, indicating that Notch1 and Shh signaling underlies the chemoresistance of GATICs\[[@B110]\]. Another well-recognized GATIC cell marker is CD44, which also confers GATICs with the capacity of drug resistance\[[@B111]\]. Chemoresistant GATICs are marked by increased glycolytic flux with activated pentose phosphate pathway (PPP)\[[@B112]\]. Tamada et al\[[@B111]\] demonstrated that CD44 enhanced the glycolytic phenotype of GATICs by interacting with the pyruvate kinase M2, whereas CD44 ablation inhibited both glycolytic flux and PPP but increased intracellular level of reactive oxygen species, which are harmful to cancer cells, leading to enhanced effects of chemotherapy in hypoxia GC cells. All these mechanisms suggest that CD44 contributes to chemoresistance of GC cells through metabolic modulation. Other studies claim that stemness-related signaling pathways, including the PI3K/AKT signaling pathway and the WNT/β-catenin signaling pathway, also contribute to chemoresistance through their interaction with CD133 and ABCG2, respectively\[[@B110]\]. Moreover, the cancer cell-stroma interface of the TIC niches within tumor microenvironment hinders the drug entrance, and thereby reduces the efficiency of chemotherapy\[[@B113]\]. These findings facilitate the design of therapeutic agents that specifically target GATICs and thereby improve the drug efficiency.

GATIC-Targeted therapies
------------------------

Based on the uncovered mechanisms of chemoresistance, two major strategies for elimination of the GATIC population have been developed: differentiation therapy and elimination therapy\[[@B114]\]. The former one implies treatment that induces GATIC differentiation to suppress their self-renewal capacity, and thereby making GC progression unsustainable in the long run. Han et al\[[@B115]\] reported that ATOH1, a helix-loop-helix transcription factor, was induced during GATIC differentiation. They demonstrated that overexpression of ATOH1 in GATICs induced their differentiation and reduced their tumorigenicity both *in vitro* and *in vivo*, suggesting ATOH1 as a potential target for differentiation therapy targeting GATICs\[[@B115]\]. Similarly, lentiviral vector-based knockdown of PGK1, a metabolic enzyme that is involved in the dissemination of GC cells, induced the differentiation of the CD44(+) GATIC population and significantly inhibited both tumor growth and metastasis in immunodeficient mice\[[@B116]\]. These studies imply the feasibility of differentiation therapy to overcome chemoresistance of GC, although no therapeutic agent has yet been developed or entered clinical trials.

The other strategy to eliminate directly GATICs mainly focuses on self-renewal signaling pathways that are aberrantly overexpressed in GATICs. For instance, the SHH signaling pathway is abnormally dysregulated in GATICs. Ptch and Gli1 are two key SHH pathway genes targeted by cyclopamine\[[@B117]\]. Song et al\[[@B80]\] reported that treatment of cyclopamine not only caused an enhanced reduction in self-renewal capacity but also improved the efficacy of oxaliplatin on GATIC-enriched tumor sphere cells. Vismodegib is another SHH pathway inhibitor that directly binds to SMO and subsequently inhibits the activation of downstream GLI family of transcription factors and their regulation on target genes\[[@B118]\]. A biomarker-based analysis of a phase 2 clinical trial of Vismodegib combined with FOLFOX *vs* FOLFOX demonstrated that Vismodegib could potentially reverse chemotherapy resistance in the population of patients with high CD44-expressing GC tumors\[[@B119]\]. Another featured pathway in GATICs is the Wnt/β-catenin signaling pathway, which is essentially involved in maintenance of TIC properties and induction of EMT. Gupta et al\[[@B120]\] conducted a high-throughput screening to identify selective TIC inhibitors and discovered that salinomycin, a specific suppressor of Wnt/β-catenin pathway, potently inhibited TICs in multiple cancer types. Zhi et al\[[@B121]\] subsequently observed that chemoresistant GATICs highly expressing ALDH were relatively sensitive to salinomycin when compared to ALDH-low GC cells, indicating salinomycin as a selective therapy for GATIC fraction. Similarly, Liu et al\[[@B122]\] reported that ICG-001, a small molecule disrupting the co-activator of Wnt/β-catenin-mediated transcription, significantly suppressed GC cell growth, reduced their stemness properties, and enhanced their chemosensitivity to 5-Fu and cisplatin. Napabucasin is an orally administered small molecule that inhibits STAT3, β-catenin, and NANOG. Several studies have demonstrated its potent anti-stemness effect in various types of cancers\[[@B121]\]. A phase Ib/II clinical trial of Napabucasin combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma not only demonstrated its safety but also observed its anti-cancer activity, leading to an on-going phase III study of Napabucasin in combination with weekly paclitaxel as the second-line treatment for gastric/GEJ cancer\[[@B123]\]. Moreover, since overexpression of ABC transporters in GATICs leads to substantial efflux of therapeutic agents and chemoresistance, it is postulated that selectively inhibiting ABC transporters may be an alternative strategy to tackle chemoresistance. Indeed, multiple ABC transporter inhibitors (especially targeting ABCG2) have been recently developed to sensitize multidrug resistant (MDR) cancer cells\[[@B124],[@B125]\]. Although some promising effects of improving chemosensitivity have been observed, significant side effects, such as cytotoxic effects on normal stem cells and blood-brain barrier, imply that substantial caution should be applied to obtain optimal outcomes\[[@B126]\]. So far, there are multiple developed therapeutic strategies targeting GATICs, either in the preclinical phase of experimental investigation or being tested in the clinical trials as developed chemotherapeutic agents. The most representative examples are shown in Table [2](#T2){ref-type="table"}\[[@B127]-[@B137]\].

###### 

Gastric tumor-initiating cell-targeted therapeutic strategies/agents

  **Therapeutic target**            **Therapeutic agent**     **Investigation status**                                                                                               **Underlying mechanism**                                                                                                                      **Treatment**                                                                     **Result of treatment**                                                                                                                                                                                    **Ref**.
  --------------------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  ATOH1                             Lentiviral vector-based   Preclinical investigation                                                                                              Overexpression of ATOH1 mediates its transcriptional activity to downstream genes and induces the differentiation of GATICs                   Lentiviral vector-based overexpression of ATOH1                                   \(1\) Induction of CD44+/Lgr5+ GATICs differentiation (2) Reduced tumorigenicity of GATICs both *in vitro* and *in vivo*                                                                                   Han et al\[[@B115]\]
  PGK1                              Lentiviral vector-based   Preclinical investigation                                                                                              Knockdown of PGK1 alters the glycolytic metabolism of GATICs not only induces GATIC differentiation but also improve their chemosensitivity   Lentiviral vector-based knockdown of PGK1                                         \(1\) Induction of CD44+ GATICs differentiation (2) Inhibited tumor growth and metastasis *in vivo*                                                                                                        Zieker et al\[[@B116]\]
  CD44v                             Sulfasalazine             Phase I dose-escalation clinical study in EPOC1205                                                                     Targeting CD44v by inhibiting xCT which mainly interacts with CD44v and maintains high level of GSH                                           12 g/d, 4x/d with 2 wk as one cycle, oral administration                          Reduced level of CD44v positive GATICs in some patients                                                                                                                                                    Shitara et al\[[@B130]\]
  EpCam                             Catumaxomab               Phase II/III clinical trial of advanced gastric carcinoma_NCT00836654                                                  Direct targeting CD3 and EpCam                                                                                                                Paracentesis +/- Catumaxomab                                                      Clinical benefit (prolonged PFS and less symptoms of ascites) in GC patients with secondary malignant ascites                                                                                              Heiss et al\[[@B131]\]
  EpCam                             Catumaxomab               Phase II clinical trial of advanced gastric carcinoma_NCT01784900                                                      Direct targeting CD3 and EpCam                                                                                                                Surgical resection followed by Catumaxomab                                        Intra-/postoperative administration of catumaxomab within multimodal treatment is feasible and tolerable                                                                                                   Goéré et al\[[@B132]\]
  c-MET                             Rilotumumab               Phase III clinical trial of locally advanced or metastatic gastric and GEJ carcinoma_NCT01697072                       Competitively targeting hepatocyte growth factor (HGF), ligand of c-MET receptor                                                              ECX +/- Rilotumumab                                                               Stopped early due to increased death risk                                                                                                                                                                  Doshi et al\[[@B133]\]
  c-MET                             Onartuzumab               Phase III clinical trial of metastatic HER2(-) and c-MET(+) Gastroesophageal Cancer_NCT01662869                        Direct targeting c-MET as a MET antagonist                                                                                                    FOLFOX6 +/- Rilotumumab                                                           Insignificant prolong of PFS (6.9 mo *vs* 5.7 mo) and OS (11.0 mo *vs* 9.7 mo)                                                                                                                             Shah *et a*l\[[@B134]\]
  c-MET                             Tivantinib                Phase I/II clinical trial of advanced and metastatic adenocarcinoma of distal esophagus, GEJ and stomach_NCT01611857   Inhibition of c-Met receptor tyrosine kinase                                                                                                  FOLFOX6 combined with Tivantinib                                                  PFS: 6.1 mo and OS: 9.6 mo                                                                                                                                                                                 Pant *et a*l\[[@B135]\]
  SHH signaling pathway             Cyclopamine               Preclinical investigation                                                                                              Targeting overexpressed Ptch/Gli1 (key effectors in SHH pathway)                                                                              Direct addition of cyclopamine (5 μmol/L *in vitro* and 10 μmol/L *in vivo*)      \(1\) Reduced self-renewing capacity of GATIC-enriched tumor sphere (2) Enhanced efficacy of Oxaliplatin/Mitomycin inhibiting proliferation of tumor sphere                                                Song et al\[[@B80]\]
  SHH signaling pathway             Vismodegib                Phase II clinical trial of advanced gastric and GEJ carcinoma_NCT00982592                                              Targeting Smoothened (SMO) and its downstream GLI family members                                                                              FOLFOX +/- Vismodegib                                                             \(1\) No significant improvement of anti-tumor activity (2) Potentially reverse the chemotherapy resistance of patients with high CD44-expressing tumor cells                                              Cohen et al\[[@B136]\]
  Wnt/β-catenin signaling pathway   Salinomycin               Preclinical investigation                                                                                              Blocking and degrading LRP6 (Wnt co-receptor)                                                                                                 Direct addition of Salinomycin (ranging from 1 μmol/L to 100 μmol/L *in vitro*)   Effectively kill ALDH-high GATICs which are resistant to 5-FU and CDDP                                                                                                                                     Mao et al\[[@B87]\]
  Wnt/β-catenin signaling pathway   ICG-001                   Preclinical investigation                                                                                              Inhibiting CBP (co-activator of Wnt/β-catenin pathway)                                                                                        Direct addition of ICG-001 (50 mg/kg/d, *in vivo*)                                \(1\) Suppressed GC cell growth and metastasis both *in vitro* and *in vivo* (2) Reduced self-renewal capacity and enhanced efficacy of 5-Fu/cisplatin                                                     Liu et al\[[@B122]\]
  STAT3 signaling pathway           Napabucasin               Phase Ib/II dose-escalation and extension study of advanced gastric and GEJ carcinoma_NCT01325441                      Direct targeting Stat3, β-catenin and NANOG                                                                                                   Paclitaxel +/- Napabucasin                                                        \(1\) Well-tolerated by GC patients even receiving high doses of chemotherapy (2) Observed anti-tumor activity but still needs to be further confirmed in the on-going BRIGHTER phase III clinical trial   Shah et al\[[@B137]\]

GATIC: Gastric tumor-initiating cell; SHH: Sonic hedgehog; GEJ: Gastroesophageal junction; GC: Gastric cancer; ALDH: Aldehyde dehydrogenase.

CONCLUSION
==========

The complexity of GC remains largely unsolved due to its heterogeneity, especially intratumor heterogeneity. TIC model is proposed to interpret the heterogeneity of GC. Accumulating TIC investigations demonstrate that GATICs contribute to intratumor heterogeneity under the influence of genetic/epigenetic and microenvironmental factors. Recent studies show the bidirectional conversion between TIC and non-TIC status, indicating the plasticity of GATICs. Although the underlying mechanisms of this scenario have been studied to some extent, it remains unclear how GATICs are regulated and influenced by intrinsic and extrinsic factors. Technological advances in genomic, especially sequencing technique at the single cell level, could trace the developing route of individual GC cells and potentially better model the intertwined relationships between GATICs and their regulatory factors. With respect to the GATIC-target therapy, several *in vitro* and/or *in vivo* functional experiments have demonstrated that targeting GATICs reduced chemoresistance and thereby improved the outcomes of drug treatment. However, the disparity of drug effects between preclinical studies and clinical trials has also been repeatedly observed. One major explanation is that current *in vitro* and *in vivo* models failed to recapitulate the real TME that plays crucial roles in regulating GATIC phenotypes and plasticity. With the application of Matrigel^®^ and other specific cell culture materials, three-dimensional spheroid and even organoid cultures of GC have been recently generated to enrich TIC subpopulation and mimic the real status of GC cells within the microenvironment. As stroma and ECM, key aspects of TME, are still missing in current cultivation system, new methods, such as co-culture of patient-derived cancer cells and stromal cells within the ECM-like "scaffolds", will be developed in the near future to represent better the tumor heterogeneity.
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